Your browser doesn't support javascript.
Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease.
Okuhama, Ayako; Hotta, Masatoshi; Ishikane, Masahiro; Kawashima, Akira; Miyazato, Yusuke; Terada, Mari; Yamada, Gen; Kanda, Kohei; Inada, Makoto; Sato, Lubna; Sato, Mitsuhiro; Akiyama, Yutaro; Suzuki, Tetsuya; Nakamoto, Takato; Nomoto, Hidetoshi; Ide, Satoshi; Nakamura, Keiji; Saito, Sho; Kinoshita, Noriko; Yamamoto, Kei; Morioka, Shinichiro; Ujiie, Mugen; Hayakawa, Kayoko; Kustuna, Satoshi; Shida, Yoshitaka; Tajima, Tsuyoshi; Teruya, Katsuji; Funato, Yumi; Yamamoto, Makiko; Izumi, Shinyu; Hojo, Masayuki; Sugiyama, Haruhito; Ohmagari, Norio.
  • Okuhama A; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Hotta M; Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ishikane M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.
  • Kawashima A; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Miyazato Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Terada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Yamada G; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kanda K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Inada M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sato L; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sato M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Akiyama Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Suzuki T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Nakamoto T; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Nomoto H; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ide S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Nakamura K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Saito S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kinoshita N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Yamamoto K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Morioka S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Ujiie M; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Hayakawa K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kustuna S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Shida Y; Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Tajima T; Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Teruya K; AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
  • Funato Y; Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan.
  • Yamamoto M; Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan.
  • Izumi S; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Hojo M; Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
  • Sugiyama H; National Center for Global Health and Medicine, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
J Infect Chemother ; 28(2): 217-223, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1654760
ABSTRACT

OBJECTIVES:

To alleviate the overflow of coronavirus disease 2019 (COVID-19) patients in hospitals, less invasive and simple criteria are required to triage the patients. We evaluated the relationship between COVID-19 severity and fatty liver on plain computed tomography (CT) scan performed on admission.

METHODS:

In this retrospective cohort study, we considered all COVID-19 patients at a large tertiary care hospital between January 31 and August 31, 2020. COVID-19 severity was categorized into severe (moderate and severe) and non-severe (asymptomatic and mild) groups, based on the Japanese National COVID-19 guidelines. Fatty liver was detected on plain CT scan. Multivariate logistic regression analysis was performed to evaluate factors associated with severe COVID-19.

RESULTS:

Of 222 patients (median age 52 years), 3.2%, 58.1%, 20.7%, and 18.0% presented with asymptomatic, mild, moderate, and severe COVID-19, respectively. Although 59.9% had no fatty liver on plain CT, mild, moderate, and severe fatty liver occurred in 13.1%, 18.9%, and 8.1%, respectively. Age and presence of fatty liver were significantly associated with severe COVID-19.

CONCLUSION:

Our study showed that fatty liver on plain CT scan on admission can become a risk factor for severe COVID-19. This finding may help clinicians to easily triage COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fatty Liver / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Middle aged Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2021.10.013

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Fatty Liver / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Middle aged Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2021.10.013